drugset / Trial / NCT00770874
Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is an open-label, multicenter, multinational, two-arm, parallel randomized Phase 3 study evaluating the efficacy and safety of S-1+Cisplatin versus single-agent Cisplatin in patients with stage IVB, recurrent or persistent carcinoma of the cervix.
Timeline
- Start
- 2008-09
- Primary completion
- 2015-12
- Completion
- 2016-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | S-1 | Small molecule | 80 mg | Oral |
| Subject | S-1 | Small molecule | 120 mg | Oral |
| Comparator | Cisplatin | Other / unclassified | 50 mg/m2 | Intravenous |